Charles Zhou
Stock Analyst at UBS
(0.95)
# 3,855
Out of 4,876 analysts
10
Total ratings
57.14%
Success rate
-10.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhou
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FUTU Futu Holdings | Maintains: Buy | $130 → $136 | $121.23 | +12.18% | 3 | Mar 17, 2025 | |
| ZYME Zymeworks | Reiterates: Buy | $16 | $12.47 | +28.31% | 1 | Mar 8, 2023 | |
| COGT Cogent Biosciences | Initiates: Buy | $15 | $7.10 | +111.27% | 1 | Jun 28, 2022 | |
| MGNX MacroGenics | Downgrades: Neutral | n/a | $1.19 | - | 1 | May 5, 2022 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $56 | $1.07 | +5,133.64% | 1 | Aug 2, 2021 | |
| RPTX Repare Therapeutics | Initiates: Buy | $46 | $1.38 | +3,233.33% | 1 | Jun 28, 2021 | |
| QD Qudian | Downgrades: Neutral | n/a | $3.09 | - | 2 | Jan 22, 2020 |
Futu Holdings
Mar 17, 2025
Maintains: Buy
Price Target: $130 → $136
Current: $121.23
Upside: +12.18%
Zymeworks
Mar 8, 2023
Reiterates: Buy
Price Target: $16
Current: $12.47
Upside: +28.31%
Cogent Biosciences
Jun 28, 2022
Initiates: Buy
Price Target: $15
Current: $7.10
Upside: +111.27%
MacroGenics
May 5, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.19
Upside: -
PMV Pharmaceuticals
Aug 2, 2021
Initiates: Buy
Price Target: $56
Current: $1.07
Upside: +5,133.64%
Repare Therapeutics
Jun 28, 2021
Initiates: Buy
Price Target: $46
Current: $1.38
Upside: +3,233.33%
Qudian
Jan 22, 2020
Downgrades: Neutral
Price Target: n/a
Current: $3.09
Upside: -